You've just added:

Potential Pulmonary Artery Hypertension Treatment Acquired

Posted on June 07, 2022 in Center for Major Diseases

Harrington Scholar in the News

Spring 2022

Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH

Chiesi Farmaceutici S.p.A. (Chiesi Group), the international research-focused pharmaceutical and healthcare group, announced it has entered into an agreement with Allinaire Therapeutics, LLC, a Harrington Project company founded by BioMotiv. Chiesi will acquire the world-wide rights to monoclonal antibodies (mAbs) against endothelial monocyte-activating polypeptide II (EMAP II) for treatment of Pulmonary Artery Hypertension (PAH). Harrington Discovery Institute provided the initial grant funding and therapeutic development services to Irina Petrache, MD, 2014 Harrington Scholar-Innovator at Indiana University and National Jewish Health.

”I received not only funding from Harrington Discovery Institute, but also a lot of help in how to take our approach, which is very academic, into a commercially appealing and valuable product.”

-Irina Petrache, MD

"This investment by Chiesi highlights our unique strength in drug discovery and development. We work with brilliant Scholars and a team of experts to advance treatment that targets the underlying cause of disease.”

- Jonathan S. Stamler, MD, President, Harrington Discovery Institute

Robert S. & Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation

Learn More

About the Scholar

Irina Petrache


Irina Petrache, MD

Indiana University
Harrington Scholar-Innovator

More about Irina Petrache

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.